Literature DB >> 16080514

Mcl-1 blocks radiation-induced apoptosis and inhibits clonogenic cell death.

Hans Skvara1, Christiane Thallinger, Volker Wacheck, Brett P Monia, Hubert Pehamberger, Burkhard Jansen, Edgar Selzer.   

Abstract

BACKGROUND: Anti-apoptotic Bcl-2 family proteins, such as Bcl-2 and Bcl-x, can modulate radio- and/or chemosensitivity of human malignancies. Since no information is available on the role Mcl-1 may play in the radioresponse of tumor cells, the relationship between Mcl-1 expression and response to ionizing radiation (IR) was investigated using an antisense strategy.
MATERIALS AND METHODS: Human melanoma cells were treated with Mcl-1 antisense oligonucleotides (ASOs) and IR. The effects of antisense treatment alone or in combination with IR on proliferation, induction of apoptosis and clonogenic cell death were evaluated.
RESULTS: ASO treatment in combination with IR reduced the mean cell numbers 9.5-fold compared to a 2.6-fold reduction after ASO treatment alone and a 1.6- fold reduction after IR alone. The percentages of apoptosis measured (means +/- SD) were 49% +/- 3.0 in antisense/IR-treated cultures compared to 1.3% +/- 0.5, 14.3% +/- 0.5, 7.3% +/- 1.1 and 10.3% +/- 0.6 in ASO controls, in antisense-treated, in IR-treated and in antisense control plus IR-treated cells, respectively. Colony formation assays demonstrated a synergistic effect of Mcl-1 down-regulation with IR.
CONCLUSION: Mcl-1 expression affects the radioresistance of human melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16080514

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  17 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.

Authors:  Yongping Shao; Andrew E Aplin
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

Review 3.  Chemosensitization of prostate cancer by modulating Bcl-2 family proteins.

Authors:  David Karnak; Liang Xu
Journal:  Curr Drug Targets       Date:  2010-06       Impact factor: 3.465

4.  Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1.

Authors:  Donatella Trivigno; Frank Essmann; Stephan M Huber; Justine Rudner
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

5.  The cyclooxygenase-2 inhibitor nimesulide, a nonsteroidal analgesic, decreases the effect of radiation therapy in head-and-neck cancer cells.

Authors:  Cornelia Czembirek; Christina Eder-Czembirek; Boban M Erovic; Dritan Turhani; Andreas Spittler; Edgar Selzer; Richard Pötter; Dietmar Thurnher
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

6.  Alteration of apoptotic signaling molecules as a function of time after radiation in human neuroblastoma cells.

Authors:  Natarajan Aravindan; Rakhesh Madhusoodhanan; Mohan Natarajan; Terence S Herman
Journal:  Mol Cell Biochem       Date:  2007-12-09       Impact factor: 3.396

7.  Mcl-1 is required for melanoma cell resistance to anoikis.

Authors:  Karen Boisvert-Adamo; Whitney Longmate; Ethan V Abel; Andrew E Aplin
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

Review 8.  Strategies for optimizing the response of cancer and normal tissues to radiation.

Authors:  Everett J Moding; Michael B Kastan; David G Kirsch
Journal:  Nat Rev Drug Discov       Date:  2013-07       Impact factor: 84.694

9.  Association of anti-apoptotic Mcl-1L isoform expression with radioresistance of oral squamous carcinoma cells.

Authors:  Vinayak C Palve; Tanuja R Teni
Journal:  Radiat Oncol       Date:  2012-08-08       Impact factor: 3.481

10.  Regulation of protein translation initiation in response to ionizing radiation.

Authors:  Donatella Trivigno; Laura Bornes; Stephan M Huber; Justine Rudner
Journal:  Radiat Oncol       Date:  2013-02-13       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.